Signosis/IL6 Responsive Luciferas Reporter HEK293 Cell Line/SL0048FP/1 Ea

Description:

IL-6ResponsiveLuciferaseReporterHEK293CellLineisderivedhumanembryonickidney,andstablyexpressfireflyluciferasereportergeneunderthecontrolofIL-6responseelement.ThiscelllineisanidealcellularmodelformonitoringtheactivationofMAPKs,PI3Ks,STATsresponsePathwaytriggeredbystimulitreatment,enforcedgeneexpressionandgeneknockdown.

Principle:

Interleukin-6(IL-6)isamultifunctionalcytokinewhichplaysanimportantroleinawiderangeofBIOLOGicprocessesindifferenttypesofcellincludingcancercells.IL6canstimulatemultiplepathwaysinvolvingMAPKs,PI3Ks,STATs,andothersignalingproteins,andsubsequentlyactivateitsdownstreamtargetsintheregulationofcellproliferation,survival,andmetabolism.EventhoughIL6wasoriginallycharacterizedasaregulatorofimmuneandinflammatoryresponses,elevatedexpressionandactivitiesofIL-6hasbeendetectedinmultiplecancers,suchasbreast,lungandlymphoma. IL-6wasassociatedwithtumorprogressionthroughincreasingantiapoptoticactivity,stimulationofangiogenesis,anddrugresistance.TheincreasedserumIL-6concentrationsinpatientsarelinkedtotheadvancedtumorstagesofvariouscancersandshortsurvivalrate.DevelopingdrugstoblockpathologicalIL-6overproductionhasbecomeapotentialtherapeuticstrategyforcancers.

 

PrinciplebehindTFluciferasereporter. TFluciferasereporterstablecelllineutilizesartificialpromoterconstructstodriveluciferaseexpression. Thepromoterregioncanconsistsofmultiplerepeatsofacis-elementTFbindingsite,aDNAfragmentfromthepromoterregionofaknownTFdownstreamgene,oraDNAfragmentcontainingputative/knownTFbindingsites. ThereareseveralwaysthataTFcanbeactivated,suchasthroughextracellularstimuliorthroughintracellularsignalingpathways. Onceactivated,theTFtranslocatestothenucleusandofteninteractswithrelevantco-factorstodrivegeneexpression. Onceluciferaseisexpressed,itcangeneratelightinanenzymaticassayandtheamountoflightmeasuredispositivelycorrelatedwiththelevelofTFactivation.

 

Data:

 

 

 

 

 

 

 

 

 

 

 

 

AnalysisofSL-0048IL-6reporteractivityinresponsetoDifferntcytokinetreatment. Thecellswereseededona96-wellplatein10%FBSDMEDmedium.Thecellsthenimmediatelyweretreatedwithorwithout10ng/mlIL-6,IL-15,IL-8,IFNr,IL-6TNFαinDMEMand10%FBSfor24hours.IL-6 inducedover40-foldincreaseinluciferaseactivitycomparedtountreatedcells.